Answers are grounded in this paper and cite their sources.
Background Cardiovascular disease remains a leading global health burden. Rhodiola rosea (RR), a botanical drug used in Tibetan, Mongolian, and Scandinavian ethnomedical traditions for cardiac fatigue and hypoxia tolerance, has been extensively studied; however, its cardioprotective potential has not been systematically summarized from an ethnopharmacological perspective. Objective This review integrates ethnomedical insights with contemporary evidence (2020–2025) to critically assess RR’s cardioprotective effects, core metabolites, and molecular mechanisms, delineating what the current evidence does and does not establish. Methods Following PRISMA 2020, PubMed, Web of Science, and CNKI were searched (January 2020–June 2025) with database-specific strategies. Evidence was appraised using an explicit hierarchy (clinical > in vivo > isolated-metabolite in vitro > extract-level in vitro > in silico ), SYRCLE and RoB 2 tools, and ConPhyMP and Four Pillars best-practice criteria. Results Of 666 records identified, 82 publications met the inclusion criteria (28 in vitro , 45 in vivo animal studies, 4 clinical studies, and 5 systematic reviews). RR’s core metabolites (salidroside, tyrosol, herbacetin, and oligomeric proanthocyanidins [OPCRR]) concurrently modulate the PI3K/Akt, Nrf2/HO-1, and AMPK/mTOR pathways; novel mechanisms include ferroptosis regulation, epigenetic modulation, and support of cardiac progenitor cell function and paracrine repair. However, the evidence is predominantly preclinical, several polyphenolic metabolites carry pan-assay interference (PAINS) liabilities, and clinical evidence remains limited to 4 small, heterogeneous studies. Conclusion RR provides a framework for bridging traditional ethnomedical use with modern pharmacology and shows multi-target cardioprotective potential across diverse preclinical models, but the current human evidence is limited and preliminary. Standardized preparations, PAINS-aware mechanistic studies, and adequately powered randomized trials are priorities for future research.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: